Frazier Life Sciences Management, L.P. Vaxcyte, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 539,405 shares of PCVX stock, worth $40.6 Million. This represents 2.65% of its overall portfolio holdings.
Number of Shares
539,405
Previous 879,405
38.66%
Holding current value
$40.6 Million
Previous $100 Million
56.02%
% of portfolio
2.65%
Previous 5.4%
Shares
9 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$900 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$796 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$748 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$654 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$467 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.46B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...